In a blow to Allergan (AGN), the U.S. Supreme Court rebuffed its effort to shield patents on a best-selling drug from a review board by transferring them to a Native American tribe.

The court left intact a ruling last July by a federal appeals court that upheld the ability of the U.S. Patent Trial and Appeal Board to decide whether a half-dozen patents for the Restasis eye treatment were valid. Allergan had argued that, under federal law, the sovereign status of the Saint Regis Mohawk Tribe meant that the patents were immune from review by the patent board.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy